Investigation Launched into Fulcrum Therapeutics Following Program Discontinuation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
Source: Globenewswire
- Program Discontinuation Impact: On June 1, 2026, Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease, resulting in a significant drop in the company's stock price, reflecting market concerns about its future prospects.
- Legal Investigation Initiated: Holzer & Holzer, LLC is investigating whether Fulcrum complied with federal securities laws, indicating potential legal liabilities for the company and exacerbating investor anxiety.
- Investor Loss Advisory: Following the announcement, Fulcrum shareholders are encouraged to contact legal counsel for potential remedies due to investment losses, highlighting investor concerns regarding corporate governance and transparency.
- Law Firm Credentials: Holzer & Holzer, LLC is a highly regarded securities litigation law firm that has recovered hundreds of millions for defrauded shareholders since its inception in 2000, underscoring its expertise in protecting investor rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FULC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise
11 Analyst Rating
9 Buy
1 Hold
1 Sell
Moderate Buy
Current: 3.500
Low
7.00
Averages
16.80
High
25.00
Current: 3.500
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulcrum Therapeutics Shares Plunge 50% After FDA Safety Concerns
- FDA Safety Warning: On June 1, 2026, Fulcrum Therapeutics disclosed that the FDA raised class-wide safety concerns regarding PRC2-targeting agents, leading to a nearly 50% drop in share price, which significantly impacted investors and highlighted potential deficiencies in the company's risk management in drug development.
- Program Termination and Strategic Review: Following the FDA warning, Fulcrum immediately discontinued the development of its lead candidate pociredir and initiated a strategic review, a decision that not only affects the company's R&D direction but may also lead to a substantial decline in future revenues.
- Legal Investigation Initiated: Levi & Korsinsky law firm is investigating whether Fulcrum failed to adequately disclose material risks associated with pociredir prior to the FDA warning, which could expose the company to legal liabilities and further erode investor confidence.
- Financial Commitment Issues: Fulcrum disclosed a $25.1 million long-term lease commitment in its 10-K report filed on February 24, 2026, yet failed to mention the strategic review in its proxy materials filed on April 30, indicating a lack of transparency in information disclosure that could affect future financing capabilities.
See More
Fulcrum Therapeutics Shares Plunge 50% After FDA Safety Concerns
- FDA Safety Concerns: On June 1, 2026, Fulcrum Therapeutics disclosed that the FDA raised class-wide safety concerns regarding PRC2-targeting agents, leading to the discontinuation of its lead candidate pociredir, causing the stock to plummet approximately 50% in a single session from over $20 to around $10, severely impacting investor confidence.
- Insider Equity Holdings: The 10-K filed on February 24, 2026, revealed that certain executives held over 264,000 shares, raising questions about the company's transparency and potentially diminishing investor trust in corporate governance following the FDA announcement.
- Long-term Lease Commitment: Fulcrum disclosed a long-term lease commitment of approximately $25.1 million for office and laboratory space in its 10-K, which could exacerbate financial pressures as the company faces significant operational challenges.
- CAMP4 Agreement Value: The agreement with CAMP4 Therapeutics is valued at up to $70 million in milestones and royalties, although the upfront payment is not separately quantified, making this potential revenue stream particularly critical in light of the current crisis.
See More
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
Fulcrum Therapeutics Faces FDA Safety Issues Leading to Program Termination
- Stock Price Collapse: Fulcrum Therapeutics experienced a nearly 50% drop in stock price in a single session following the June 1, 2026 disclosure of FDA safety concerns, which not only undermines investor confidence but may also hinder future financing capabilities.
- Program Termination Impact: The immediate discontinuation of the pociredir program due to FDA feedback indicating no regulatory path forward will have profound implications for the company's R&D strategy and market competitiveness.
- Long-term Financial Commitments: The company's licensing agreement with CAMP4 includes commitments of up to $70 million in milestone payments and royalties, while the existing $25.1 million long-term lease obligation remains in place, increasing financial pressure on the company post-termination.
- Legal Investigation Initiated: Levi & Korsinsky is investigating whether Fulcrum made misleading statements regarding the outlook for pociredir, which could lead to potential securities law violations, further exacerbating investor anxiety and uncertainty.
See More
Surge in Options Trading Volume for Broadcom and Fulcrum
- Broadcom Options Volume: Broadcom Inc (AVGO) has seen an options trading volume of 343,511 contracts today, equating to approximately 34.4 million underlying shares, which represents a significant 167.6% of its average daily trading volume, indicating strong market interest in its future performance.
- High Strike Demand: The $420 strike call option for AVGO has particularly high demand, with 13,004 contracts traded today, representing about 1.3 million shares, reflecting bullish sentiment among investors regarding this price point.
- Fulcrum Options Activity: Fulcrum Therapeutics Inc (FULC) recorded an options trading volume of 9,890 contracts, translating to approximately 989,000 underlying shares, which is 162.2% of its average daily trading volume, showcasing market interest in its growth potential.
- FULC Strike Price Demand: The $4 strike call option for FULC has seen 4,585 contracts traded, representing around 458,500 shares, indicating a rising bullish sentiment among investors for this strike price.
See More
Fulcrum Therapeutics Under Investigation for Securities Violations
- Investigation Launched: Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics violated federal securities laws, focusing on investor losses and potential recovery, highlighting serious concerns regarding the company's compliance.
- Drug Development Halted: On June 1, 2026, Fulcrum announced the discontinuation of its lead drug candidate pociredir and initiated a strategic review, reflecting the regulatory challenges the company faces and its implications for future development.
- FDA Risk Assessment: Following the FDA meeting minutes from May 28, 2026, Fulcrum was informed that pharmacological interventions targeting the PRC2 complex carry equivalent malignancy risks, leading to the conclusion of “no viable regulatory path forward” for pociredir's development.
- Stock Price Plummets: Following the announcement to halt development, Fulcrum's stock price sharply declined, causing significant losses for investors and raising further questions about the management and compliance of the company.
See More
Fulcrum Therapeutics Shares Plunge 50% After FDA Safety Concerns
- FDA Safety Warning: On June 1, 2026, Fulcrum Therapeutics disclosed that the FDA raised class-wide safety concerns regarding PRC2-targeting agents, leading to a nearly 50% drop in share price, which significantly impacted investors and highlighted potential deficiencies in the company's risk management in drug development.
- Program Termination and Strategic Review: Following the FDA warning, Fulcrum immediately discontinued the development of its lead candidate pociredir and initiated a strategic review, a decision that not only affects the company's R&D direction but may also lead to a substantial decline in future revenues.
- Legal Investigation Initiated: Levi & Korsinsky law firm is investigating whether Fulcrum failed to adequately disclose material risks associated with pociredir prior to the FDA warning, which could expose the company to legal liabilities and further erode investor confidence.
- Financial Commitment Issues: Fulcrum disclosed a $25.1 million long-term lease commitment in its 10-K report filed on February 24, 2026, yet failed to mention the strategic review in its proxy materials filed on April 30, indicating a lack of transparency in information disclosure that could affect future financing capabilities.
See More
Fulcrum Therapeutics Shares Plunge 50% After FDA Safety Concerns
- FDA Safety Concerns: On June 1, 2026, Fulcrum Therapeutics disclosed that the FDA raised class-wide safety concerns regarding PRC2-targeting agents, leading to the discontinuation of its lead candidate pociredir, causing the stock to plummet approximately 50% in a single session from over $20 to around $10, severely impacting investor confidence.
- Insider Equity Holdings: The 10-K filed on February 24, 2026, revealed that certain executives held over 264,000 shares, raising questions about the company's transparency and potentially diminishing investor trust in corporate governance following the FDA announcement.
- Long-term Lease Commitment: Fulcrum disclosed a long-term lease commitment of approximately $25.1 million for office and laboratory space in its 10-K, which could exacerbate financial pressures as the company faces significant operational challenges.
- CAMP4 Agreement Value: The agreement with CAMP4 Therapeutics is valued at up to $70 million in milestones and royalties, although the upfront payment is not separately quantified, making this potential revenue stream particularly critical in light of the current crisis.
See More
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
Fulcrum Therapeutics Faces FDA Safety Issues Leading to Program Termination
- Stock Price Collapse: Fulcrum Therapeutics experienced a nearly 50% drop in stock price in a single session following the June 1, 2026 disclosure of FDA safety concerns, which not only undermines investor confidence but may also hinder future financing capabilities.
- Program Termination Impact: The immediate discontinuation of the pociredir program due to FDA feedback indicating no regulatory path forward will have profound implications for the company's R&D strategy and market competitiveness.
- Long-term Financial Commitments: The company's licensing agreement with CAMP4 includes commitments of up to $70 million in milestone payments and royalties, while the existing $25.1 million long-term lease obligation remains in place, increasing financial pressure on the company post-termination.
- Legal Investigation Initiated: Levi & Korsinsky is investigating whether Fulcrum made misleading statements regarding the outlook for pociredir, which could lead to potential securities law violations, further exacerbating investor anxiety and uncertainty.
See More
Surge in Options Trading Volume for Broadcom and Fulcrum
- Broadcom Options Volume: Broadcom Inc (AVGO) has seen an options trading volume of 343,511 contracts today, equating to approximately 34.4 million underlying shares, which represents a significant 167.6% of its average daily trading volume, indicating strong market interest in its future performance.
- High Strike Demand: The $420 strike call option for AVGO has particularly high demand, with 13,004 contracts traded today, representing about 1.3 million shares, reflecting bullish sentiment among investors regarding this price point.
- Fulcrum Options Activity: Fulcrum Therapeutics Inc (FULC) recorded an options trading volume of 9,890 contracts, translating to approximately 989,000 underlying shares, which is 162.2% of its average daily trading volume, showcasing market interest in its growth potential.
- FULC Strike Price Demand: The $4 strike call option for FULC has seen 4,585 contracts traded, representing around 458,500 shares, indicating a rising bullish sentiment among investors for this strike price.
See More
Fulcrum Therapeutics Under Investigation for Securities Violations
- Investigation Launched: Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics violated federal securities laws, focusing on investor losses and potential recovery, highlighting serious concerns regarding the company's compliance.
- Drug Development Halted: On June 1, 2026, Fulcrum announced the discontinuation of its lead drug candidate pociredir and initiated a strategic review, reflecting the regulatory challenges the company faces and its implications for future development.
- FDA Risk Assessment: Following the FDA meeting minutes from May 28, 2026, Fulcrum was informed that pharmacological interventions targeting the PRC2 complex carry equivalent malignancy risks, leading to the conclusion of “no viable regulatory path forward” for pociredir's development.
- Stock Price Plummets: Following the announcement to halt development, Fulcrum's stock price sharply declined, causing significant losses for investors and raising further questions about the management and compliance of the company.
See More
